Electromedical Technologies Inc (EMED)

[Winsmore]

$EMED
AI Overview:
If Electromedical Technologies (EMED) does not withdraw its Form 15 by the 90-day deadline, it will automatically delist from its exchange and no longer be an SEC-reporting company. This action would align with a potential reverse merger or roll-up acquisition, particularly given the prior announcements of a joint venture and potential acquisition involving Lionheart Health.

Background on Form 15 and delisting
• What is Form 15? A company files Form 15 to voluntarily suspend its duty to file periodic reports (such as 10-Qs and 10-Ks) with the U.S. Securities and Exchange Commission (SEC).
• Initial effects: The filing immediately suspends reporting obligations. The SEC will issue a notice of delisting after 90 days if the company has not withdrawn the filing.
• Impact of delisting: A delisted company no longer needs to make public disclosures, which is a key part of the reverse merger process. It becomes a more attractive "shell" company for a private company seeking to go public.

Potential scenarios involving Lionheart Health

Reverse merger
A reverse merger, or reverse takeover, is a likely scenario if EMED does not withdraw its Form 15. In this process, a private company (Lionheart) would acquire a public shell company (EMED).
• How it would work: Lionheart Health's owners would acquire a majority stake in Electromedical Technologies. The combined company would then take on the name and business of Lionheart, which is already a partner in a joint venture with EMED.
• Why it's likely: Lionheart's CEO stated in a May 2024 interview that it planned a roll-up acquisition of partners like EMED before a late 2025 or 2026 IPO. This timeline aligns with EMED's Form 15, filed in July 2025, which would complete the shell process before the planned acquisition.

Roll-up acquisition
This is a specific type of acquisition strategy that also fits the situation.
• How it would work: A larger company or investment group, such as Lionheart's parent company, Leonhardt Ventures, would systematically acquire smaller, related companies in a fragmented industry.
• Why it's likely: Lionheart's CEO has described plans to acquire its key suppliers and partners, which would include EMED, before going public. This consolidation would allow the combined entity to leverage economies of scale and pursue its planned IPO.

Awaiting the deadline
The ultimate meaning behind EMED not withdrawing its Form 15 depends on the specific actions and intent of the companies involved.
• The most probable outcome is that Electromedical Technologies is preparing to be acquired by Lionheart Health in either a reverse merger or roll-up.
• This would allow Lionheart to access public markets more quickly and cheaply than through a traditional IPO.
• The delisting process is a key preparatory step for this type of transaction, clearing the way for the private company to take control of the newly formed public entity.